State Street Corp Akebia Therapeutics, Inc. Transaction History

State Street Corp

$2.59 Trillion
Q2 2025

A detailed history of State Street Corp transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 7,997,153 shares of AKBA stock, worth $26.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,997,153

Previous 6,805,807 17.5%

Holding current value

$26.6 Million

Previous $13.1 Million 122.77%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.55 - $3.97 $1.85 Million - $4.73 Million	1,191,346 Added 17.5%	7,997,153 $29.1 Million
Q1 2025 May 15, 2025	BUY	$1.69 - $2.84 $846,874 - $1.42 Million	501,109 Added 7.95%	6,805,807 $13.1 Million
Q4 2024 Feb 14, 2025	BUY	$1.26 - $2.13 $3.62 Million - $6.12 Million	2,874,171 Added 83.78%	6,304,698 $11.7 Million
Q3 2024 Nov 14, 2024	BUY	$0.94 - $1.55 $642,289 - $1.06 Million	683,287 Added 24.87%	3,430,527 $4.53 Million
Q2 2024 Aug 14, 2024	BUY	$0.86 - $1.63 $1.8 Million - $3.42 Million	2,096,890 Added 322.42%	2,747,240 $2.8 Million
Q1 2024 May 15, 2024	BUY	$1.27 - $2.24 $50,546 - $89,152	39,800 Added 6.52%	650,350 $1.19 Million
Q4 2023 Feb 14, 2024	SELL	$0.8 - $1.28 $36,720 - $58,752	-45,900 Reduced 6.99%	610,550 $757,000
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.84 $26,448 - $55,936	30,400 Added 4.86%	656,450 $748,000
Q2 2023 Aug 14, 2023	SELL	$0.51 - $1.43 $34,060 - $95,503	-66,786 Reduced 9.64%	626,050 $575,000
Q1 2023 May 15, 2023	BUY	$0.56 - $1.15 $67,704 - $139,035	120,900 Added 21.14%	692,836 $387,000
Q3 2022 Nov 15, 2022	SELL	$0.3 - $0.46 $582 - $892	-1,940 Reduced 0.34%	571,936 $181,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $3.49 Million - $7.31 Million	-10,914,348 Reduced 95.0%	573,876 $203,000
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $183,770 - $747,844	-255,237 Reduced 2.17%	11,488,224 $8.25 Million
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $9.3 Million - $13.7 Million	-4,112,967 Reduced 25.94%	11,743,461 $26.5 Million
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $4.35 Million - $7.18 Million	1,849,791 Added 13.21%	15,856,428 $45.7 Million
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $8.6 Million - $12.8 Million	-3,037,539 Reduced 17.82%	14,006,637 $53.1 Million
Q1 2021 May 17, 2021	SELL	$2.92 - $5.06 $15.9 Million - $27.5 Million	-5,432,358 Reduced 24.17%	17,044,176 $57.7 Million
Q4 2020 Feb 16, 2021	BUY	$2.22 - $3.78 $15.8 Million - $27 Million	7,136,063 Added 46.52%	22,476,534 $62.9 Million
Q3 2020 Nov 10, 2020	BUY	$2.39 - $13.08 $24.7 Million - $135 Million	10,328,433 Added 206.07%	15,340,471 $38.5 Million
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $10.6 Million - $21.7 Million	1,595,108 Added 46.68%	5,012,038 $68.1 Million
Q1 2020 May 11, 2020	BUY	$4.1 - $10.24 $14 Million - $35 Million	3,416,930 New	3,416,930 $25.9 Million

Others Institutions Holding AKBA

# of Institutions

169

Shares Held

105M

Call Options Held

134K

Put Options Held

262K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $610M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Akebia Therapeutics, Inc. Transaction History